Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

SAN FRANCISCO, Nov. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced the expansion of its clinical advisory board. Joining the clinical advisory board's chair, Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School, and Senior Physician, Brigham & Women's Hospital in Boston, and Jean-Claude Tardif, M.D., Associate Professor of Medicine, University of Montreal, and Director of Research, Montreal Heart Institute, are Marcelo Di Carli, M.D., Associate Professor of Radiology, and Chief of Nuclear Medicine, Brigham and Women's Hospital; Robert Fenichel, M.D., Ph.D, Former Deputy Division Director, Division of CardioRenal Drug Products, Food and Drug Administration; Peter Libby, M.D., Mallinckrodt Professor of Medicine, and Chief, Cardiovascular Division, Brigham and Women's Hospital; and, Jean-Lucien Rouleau, M.D., Dean, Faculty of Medicine, University of Montreal.

"The addition of these well-respected physicians to VIA's clinical advisory board comes at an important time in our history," said Larry Cohen, Ph.D., president and chief executive officer of VIA. "As we prepare for the release of Phase II clinical trial data in the middle of 2008, our clinical advisory board will provide independent medical, scientific, and regulatory guidance in supporting our efforts to advance VIA-2291 as a treatment of cardiovascular disease."

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversib
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... Texas (PRWEB) August 31, 2014 ... the current state of the Epoxy Hardener ... a basic overview of the industry, including definitions, ... and Chinese domestic market analysis are provided with ... landscape of the market. A comparison between the ...
(Date:8/29/2014)... August 29, 2014 The global ... billion in 2019. It is expected to grow ... 2019, and was valued at $1.8 billion in ... Transparency Market Research. , For more information regarding ... . , The research report, titled “Companion Diagnostics ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Multiporator , , , , , , , ... Protocol No. 4308 915.040 11/2000 , , , , ... , Cell line , U-266, human myeloma, ... Plasmid pEGFP-C1 (in bidistilled H 2 O), , ...
... , , , , , , ... , , , , , , , ... Cell line , T98G, human glioblastoma, , ... (in bidistilled H 2 O), , , ...
... , , , , , , , Multiporator / Electroporator 2510 , ... , Transformation Protocol , Protocol ... , , , , , ... , , Cell type , ...
Cached Biology Technology:U-266 2T98G 2Staphylococcus epidermidis 2
(Date:9/2/2014)... regulations over the last decade in Taiyuan, China, have ... for a greater than 50% reduction in costs associated ... 2010, according to researchers at the Columbia Center for ... Public Health, the Shanxi Medical University, the Center of ... Fudan University School of Public Health. , The study ...
(Date:9/2/2014)... take stress in stride; others are done in by ... molecular mechanisms of this so-called stress gap in mice ... could lead researchers to better understand the development of ... people, each animal has unique experiences as it goes ... experiences can alter the expression of genes, and as ...
(Date:9/1/2014)... Conventional wisdom has long held that corals ... reefs are passive organisms that rely entirely ... as nutrients and oxygen. But now scientists at ... in Israel have found that they are far ... into turbulent patterns that greatly enhance their ability ...
Breaking Biology News(10 mins):Clean air halves health costs in Chinese city 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Nature's tiny engineers 2Nature's tiny engineers 3
... at the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory ... of carbon can be used to image aromatase, an enzyme ... The research, published in the November issue of Synapse ... aromatase is concentrated may be unique to humans. "The ...
... crisis in a similar way to plants and the human ... to predict future financial down-turns. An extensive analysis of ... similar symptoms, whether they be polluted forests, cancer patients or ... the way that humans, animals and plants adapt to harsh ...
... now dominate the field of veterinary medicine the result ... itself in the fields of medicine and law. That,s ... that appear to be driving the change: the 1972 federal ... graduate schools who may be deterred by a growing number ...
Cached Biology News:PET scans reveal estrogen-producing hotspots in human brain 2Plants and animals under stress may provide the key to better stock market predictions 2Vet med's big shift to more women, fewer men driven by falling barriers, more female grads 2Vet med's big shift to more women, fewer men driven by falling barriers, more female grads 3Vet med's big shift to more women, fewer men driven by falling barriers, more female grads 4